Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Overlooked cases of HIV infection: An Italian tale of missed diagnostic opportunities.

van den Bogaart L, Ranzani A, Oreni L, Giacomelli A, Corbellino M, Rusconi S, Galli M, Antinori S, Ridolfo AL.

Eur J Intern Med. 2019 Oct 18. pii: S0953-6205(19)30319-X. doi: 10.1016/j.ejim.2019.09.006. [Epub ahead of print]

PMID:
31635999
2.

No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.

Giacomelli A, Lai A, Franzetti M, Maggiolo F, Di Giambenedetto S, Borghi V, Francisci D, Magnani G, Pecorari M, Monno L, Vicenti I, Lepore L, Lombardi F, Paolucci S, Rusconi S; ARCA collaborative group.

Antiviral Res. 2019 Oct 17;172:104635. doi: 10.1016/j.antiviral.2019.104635. [Epub ahead of print]

PMID:
31629714
3.

Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study.

Modica S, Redi D, Gagliardini R, Giombini E, Bezenchek A, Di Carlo D, Maggiolo F, Lombardi F, Borghetti A, Farinacci D, Callegaro A, Gismondo MR, Colafigli M, Sterrantino G, Costantini A, Ferrara SM, Rusconi S, Zazzi M, Rossetti B, De Luca A, Gianotti N.

J Antimicrob Chemother. 2019 Oct 11. pii: dkz424. doi: 10.1093/jac/dkz424. [Epub ahead of print]

PMID:
31605107
4.

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

Mussini C, Roncaglia E, Borghi V, Rusconi S, Nozza S, Cattelan AM, Segala D, Bonfanti P, Di Biagio A, Barchi E, Focà E, Degli Antoni A, Bonora S, Francisci D, Limonta S, Antinori A, D'Ettorre G, Maggiolo F.

PLoS One. 2019 Sep 27;14(9):e0222650. doi: 10.1371/journal.pone.0222650. eCollection 2019.

5.

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.

Baldin G, Ciccullo A, Rusconi S, Capetti A, Sterrantino G, Colafigli M, d'Ettorre G, Giacometti A, Cossu MV, Borghetti A, Gennari W, Mussini C, Borghi V, Di Giambenedetto S.

Int J Antimicrob Agents. 2019 Sep 12. pii: S0924-8579(19)30245-6. doi: 10.1016/j.ijantimicag.2019.09.002. [Epub ahead of print]

PMID:
31521809
6.

A push for 90-90-90: Initial treatment with INSTI-based regimens against HIV-1 infection.

Rusconi S, Giacomelli A.

EClinicalMedicine. 2019 Jul 20;13:4-5. doi: 10.1016/j.eclinm.2019.07.004. eCollection 2019 Aug. No abstract available.

7.

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.

Giacomelli A, Ranzani A, Oreni L, Gervasi E, Lupo A, Ridolfo AL, Galli M, Rusconi S.

Drug Des Devel Ther. 2019 Jul 9;13:2271-2282. doi: 10.2147/DDDT.S204415. eCollection 2019.

8.

Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.

Rossetti B, Baldin G, Sterrantino G, Rusconi S, De Vito A, Giacometti A, Gagliardini R, Colafigli M, Capetti A, d'Ettorre G, Celani L, Lagi F, Ciccullo A, De Luca A, Di Giambenedetto S, Madeddu G.

Antiviral Res. 2019 Sep;169:104552. doi: 10.1016/j.antiviral.2019.104552. Epub 2019 Jul 5.

PMID:
31283942
9.

Impact of genotypic susceptibility score on cART outcomes during primary HIV infection.

Giacomelli A, Fabbiani M, De Benedetto I, Nozza S, Focà E, Celesia BM, Marchetti G, Mussini C, Antinori A, d'Ettorre G, Madeddu G, Bandera A, Muscatello A, Rusconi S.

J Med Virol. 2019 Oct;91(10):1891-1895. doi: 10.1002/jmv.25517. Epub 2019 Jun 27.

PMID:
31199538
10.

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study.

Antinori A, Rusconi S, Gianotti N, Bini T, Mancusi D, Termini R.

Drug Des Devel Ther. 2019 May 14;13:1667-1685. doi: 10.2147/DDDT.S180981. eCollection 2019.

11.

Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use.

Maggi P, De Socio GV, Cicalini S, D'Abbraccio M, Dettorre G, Di Biagio A, Martinelli C, Nunnari G, Rusconi S, Sighinolfi L, Spagnuolo V, Squillace N.

AIDS Res Ther. 2019 May 24;16(1):11. doi: 10.1186/s12981-019-0226-2.

12.

Is the rate of virological failure to cART continuing to decline in recent calendar years?

Rusconi S, Santoro MM, Gianotti N, Antinori A, Bonora S, Cingolani A, Ceccherini Silberstein F, Tavelli A, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group.

J Clin Virol. 2019 Jul;116:23-28. doi: 10.1016/j.jcv.2019.04.009. Epub 2019 May 3.

13.

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.

Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group.

Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3309. [Epub ahead of print]

PMID:
30977466
14.

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, Baldin GM, Soria A, Riccardi N, Niero FP, Celesia BM, Barbarini G, Rusconi S, Rizzardini G.

HIV Clin Trials. 2018 Dec;19(6):242-248. doi: 10.1080/15284336.2018.1550290.

PMID:
30890064
15.

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.

Castagna A, Rusconi S, Gulminetti R, Bonora S, Mazzola G, Quiros-Roldan ME, De Socio GV, Ladisa N, Carosella S, Cattelan A, Di Giambenedetto S, Mena M, Poli A, Galli L, Riva A; DAU Study Group.

AIDS. 2019 Jun 1;33(7):1256-1260. doi: 10.1097/QAD.0000000000002188.

PMID:
30870194
16.

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.

Rossetti B, Gagliardini R, Sterrantino G, Colangeli V, Latini A, Colafigli M, Vignale F, Rusconi S, Di Biagio A, Orofino G, Mezzaroma I, Vullo V, Francisci D, Mastroianni C, Trezzi M, Canovari B, Lamonica S, Ciccullo A, Borghetti A, DʼArminio Monforte A, Di Giambenedetto S, De Luca A; for GUSTA trial study group.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986. No abstract available.

17.

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.

d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, Marchetti G, Lo Caputo S, Rusconi S, Gianotti N, Mazzotta V, Mazzarello G, Costantini A, Castagna A, Antinori A; ICONA Foundation Study Group.

J Antimicrob Chemother. 2019 May 1;74(5):1363-1367. doi: 10.1093/jac/dky566.

PMID:
30698801
18.

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.

Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group.

J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227.

19.

Clinical pharmacology in HIV cure research - what impact have we seen?

Giacomelli A, de Rose S, Rusconi S.

Expert Rev Clin Pharmacol. 2019 Jan;12(1):17-29. doi: 10.1080/17512433.2019.1561272. Epub 2019 Jan 2. Review.

20.

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.

Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G.

HIV Med. 2019 Feb;20(2):164-168. doi: 10.1111/hiv.12688. Epub 2018 Nov 20.

PMID:
30457197
21.

Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.

Giacomelli A, Riva A, Falvella FS, Oreni ML, Cattaneo D, Cheli S, Renisi G, Di Cristo V, Lupo A, Clementi E, Rusconi S, Galli M, Ridolfo AL.

BMC Infect Dis. 2018 Nov 12;18(1):556. doi: 10.1186/s12879-018-3462-5.

22.

A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.

Ciccullo A, Baldin G, Capetti A, Rusconi S, Sterrantino G, d'Ettorre G, Colafigli M, Modica S, Lagi F, Giacomelli A, Cossu MV, Restelli S, De Luca A, Di Giambenedetto S.

Antivir Ther. 2019;24(1):63-67. doi: 10.3851/IMP3270.

PMID:
30277466
23.
24.

Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).

Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, Francisci D, Monno L, Punzi G, Meraviglia P, Paolucci S, Di Biagio A, Bruzzone B, Mancon A, Micheli V, Zazzi M; ARCA (Antiviral Response Cohort Analysis).

J Clin Virol. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21.

PMID:
29957545
25.

A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice.

Di Biagio A, Riccardi N, Rusconi S, Guaraldi G, Borderi M, De Luca A, Gianotti N, Lo Caputo S, Maggi P, Maserati R, Maggiolo F.

AIDS Rev. 2018 Apr-Jun;20(2):75-82. Review.

PMID:
29938701
26.

Clinical and genetic determinants of nevirapine plasma trough concentration.

Giacomelli A, Rusconi S, Falvella FS, Oreni ML, Cattaneo D, Cozzi V, Renisi G, Monge E, Cheli S, Clementi E, Riva A, Galli M, Ridolfo AL.

SAGE Open Med. 2018 Jun 5;6:2050312118780861. doi: 10.1177/2050312118780861. eCollection 2018.

27.

Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study.

Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A.

HIV Med. 2018 Jun 4. doi: 10.1111/hiv.12624. [Epub ahead of print]

28.

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.

Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group.

BMC Med. 2018 May 29;16(1):79. doi: 10.1186/s12916-018-1046-2.

29.

Correlation between inner retinal layer thickness and cognitive function in HIV: new insights from an exploratory study.

Invernizzi A, Acquistapace A, Bochicchio S, Resnati C, Rusconi S, Ferrari M, Leta V, Pomati S, Klistorner A, Mccluskey P, Staurenghi G, Riva A.

AIDS. 2018 Jul 17;32(11):1485-1490. doi: 10.1097/QAD.0000000000001850.

PMID:
29734219
30.

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.

Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group.

J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.

PMID:
29668978
31.

Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication.

Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Latini A, Cossu MV, Gagliardini R, De Luca A, Di Giambenedetto S.

HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12611. [Epub ahead of print]

PMID:
29573320
32.

Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.

Colella E, Cattaneo D, Galli L, Baldelli S, Clementi E, Galli M, Lazzarin A, Castagna A, Rusconi S, Spagnuolo V.

New Microbiol. 2018 Apr;41(2):106-111. Epub 2018 Mar 2.

33.

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.

Capetti AF, Cossu MV, Sterrantino G, Barbarini G, Di Giambenedetto S, De Socio GV, Orofino G, Di Biagio A, Celesia BM, Rusconi S, Argenteri B, Rizzardini G.

Ann Pharmacother. 2018 Aug;52(8):740-746. doi: 10.1177/1060028018761600. Epub 2018 Feb 26.

PMID:
29482352
34.

Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience.

Vitiello P, Taramasso L, Ricci E, Maggi P, Martinelli C, Gabrielli C, Vittorio De Socio G, Di Cristo V, Rusconi S, Falasca K, Menzaghi B, Tebini A, Di Biagio A.

J Women Aging. 2019 Mar-Apr;31(2):176-188. doi: 10.1080/08952841.2018.1428100. Epub 2018 Jan 25.

PMID:
29369016
35.

Weight Gain: A Possible Side Effect of All Antiretrovirals.

Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A; CISAI Study Group .

Open Forum Infect Dis. 2017 Nov 3;4(4):ofx239. doi: 10.1093/ofid/ofx239. eCollection 2017 Fall.

36.

Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation.

Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, Lo Caputo S, Cicalini S, Castelli F, Marchetti G, Antinori A, Monforte AD.

AIDS Patient Care STDS. 2017 Dec;31(12):487-494. doi: 10.1089/apc.2017.0140.

PMID:
29211512
37.

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort.

Nozza S, Cozzi-Lepri A, Bai F, Rusconi S, Gori A, Cinque P, Ammassari A, Caramello P, Tambussi G, D'Arminio Monforte A, Marchetti G; Icona Foundation Study Group.

PLoS One. 2017 Dec 5;12(12):e0189045. doi: 10.1371/journal.pone.0189045. eCollection 2017.

38.

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.

Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Re MC, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Grima P, Francisci D, Mastroianni C, Antinori A, Trezzi M, Lisi L, Navarra P, Canovari B, D'Arminio Monforte A, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A; for GUSTA trial study group.

PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.

39.

Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study.

Smit M, Cassidy R, Cozzi-Lepri A, Quiros-Roldan E, Girardi E, Mammone A, Antinori A, Saracino A, Bai F, Rusconi S, Magnani G, Castelli F, Hsue P, d'Arminio Monforte A, Hallett TB.

PLoS One. 2017 Oct 23;12(10):e0186638. doi: 10.1371/journal.pone.0186638. eCollection 2017.

40.

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.

Capetti AF, Cossu MV, Orofino G, Sterrantino G, Cenderello G, De Socio GV, Cattelan AM, Soria A, Rusconi S, Riccardi N, Baldin GM, Niero FP, Barbarini G, Rizzardini G.

BMC Infect Dis. 2017 Sep 30;17(1):658. doi: 10.1186/s12879-017-2755-4.

41.

Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N.

BMC Infect Dis. 2017 Aug 9;17(1):551. doi: 10.1186/s12879-017-2626-z. Review.

42.

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.

Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu G, Rusconi S, Maggi P, Celesia BM, Cordier L, Vichi F, Calza L, Falasca K, Di Biagio A, Pellicanò GF, Bonfanti P; CISAI Study Group.

PLoS One. 2017 Jun 20;12(6):e0179254. doi: 10.1371/journal.pone.0179254. eCollection 2017.

43.

Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.

Salvaggio SE, Giacomelli A, Falvella FS, Oreni ML, Meraviglia P, Atzori C, Clementi EGI, Galli M, Rusconi S.

BMC Infect Dis. 2017 Jun 5;17(1):396. doi: 10.1186/s12879-017-2497-3.

44.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group.

Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5.

PMID:
28477212
45.

Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy.

Ridolfo AL, Oreni L, Vassalini P, Resnati C, Bozzi G, Milazzo L, Antinori S, Rusconi S, Galli M.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):315-321. doi: 10.1097/QAI.0000000000001388.

PMID:
28418991
46.

Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.

Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, Rusconi S, Riccardi N, Baldin GM, Cima S, Niero FP, Rizzardini G, Sasset L.

Antivir Ther. 2017;22(3):273-275. doi: 10.3851/IMP3109. Epub 2016 Nov 28. No abstract available.

PMID:
28400541
47.

Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.

Rusconi S, Marcotullio S, Cingolani A.

New Microbiol. 2017 Apr;40(2):75-79. Epub 2017 Apr 3. Review.

48.

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group.

J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

PMID:
28093483
49.

Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.

Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group.

AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. No abstract available.

PMID:
28079545
50.

Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.

Bonfanti P, Madeddu G, Gulminetti R, Squillace N, Orofino G, Vitiello P, Rusconi S, Celesia BM, Maggi P, Ricci E; CISAI Study group.

AIDS. 2017 Jan 28;31(3):455-457. doi: 10.1097/QAD.0000000000001351. No abstract available.

PMID:
28079544

Supplemental Content

Loading ...
Support Center